DB4 - COST-EFFECTIVENESS OF DAPAGLIFLOZIN IN ADULT PATIENTS WITH INADEQUATELY CONTROLLED TYPE 1 DIABETES- A HEALTH ECONOMIC ANALYSIS USING 24-WEEK RESULTS FROM THE DEPICT-1 RANDOMISED CONTROLLED TRIAL
Oct 1, 2018, 00:00
10.1016/j.jval.2018.09.040
https://www.valueinhealthjournal.com/article/S1098-3015(18)33340-0/fulltext
Title :
DB4 - COST-EFFECTIVENESS OF DAPAGLIFLOZIN IN ADULT PATIENTS WITH INADEQUATELY CONTROLLED TYPE 1 DIABETES- A HEALTH ECONOMIC ANALYSIS USING 24-WEEK RESULTS FROM THE DEPICT-1 RANDOMISED CONTROLLED TRIAL
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(18)33340-0&doi=10.1016/j.jval.2018.09.040
First page :
Section Title :
Open access? :
No
Section Order :
2315